Fig 1.
Warfarin (1A) and 3’-hydroxywarfarin (1B) calibration curves; R expresses the ratio between the area under the analyte peak (warfarin or 3’-hydroxywarfarin respectively) and the area of the internal standard.
Table 1.
PCR multiplex amplification of DNA for primer extension.
Fig 2.
Correlation analyses between: INR, serum warfarin (ng/mL) and 3’-hydroxywarfarin (ng/mL), and the amount of drug (warfarin week) taken by the whole cohort of patients on oral anticoagulant therapy.
Fig 3.
Fluctuations of INR (A), warfarin (B) and 3’-hydroxywarfarin (C) serum concentrations among the subgroup of patients which starts oral anticoagulant therapy, during the time frame of 17–57 days (c0-c4).
Table 2.
Time-frame findings in patients starting OAT (n = 52).
Table 3.
Correlation analysis between INR and warfarin / 3’-hydroxywarfarin in the two cohorts of patients investigated.
Table 4.
Univariate and multivariate analyses to estimate the contribution of different variables on INR.
Fig 4.
Genotype distributions in the whole cohort of patients.
Different distributions of CYP2C9 haplotypes in the whole cohort of patients stratified by the three VKORC1 genotypes according to INR values (A), warfarin and 3’-hydroxywarfarin serum concentration (B, and C respectively), and warfarin week (D).
Fig 5.
Warfarin daily dose for different WRI.
Mean and median warfarin dose increased as WRI increased. WR 0, WRI 1 and WRI 2 classes are as specified in text. Continuous line indicates the median; dashed line indicates the mean, vertical bars indicate the 1st and 99th percentile of warfarin day (mg).